Literature DB >> 18219308

Prodrugs: design and clinical applications.

Jarkko Rautio1, Hanna Kumpulainen, Tycho Heimbach, Reza Oliyai, Dooman Oh, Tomi Järvinen, Jouko Savolainen.   

Abstract

Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. In both drug discovery and development, prodrugs have become an established tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents. About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend. To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18219308     DOI: 10.1038/nrd2468

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  298 in total

1.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

Review 2.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

3.  Synthesis and pharmacological evaluation of nucleoside prodrugs designed to target siderophore biosynthesis in Mycobacterium tuberculosis.

Authors:  Surendra Dawadi; Shuhei Kawamura; Anja Rubenstein; Rory Remmel; Courtney C Aldrich
Journal:  Bioorg Med Chem       Date:  2016-02-03       Impact factor: 3.641

4.  Toward multifunctional anticancer therapeutics: post-synthetic carbonate functionalisation of asymmetric Au(i) bis-N-heterocyclic carbenes.

Authors:  Sajal Sen; Mark W Perrin; Adam C Sedgwick; Evie Y Dunsky; Vincent M Lynch; Xiao-Peng He; Jonathan L Sessler; Jonathan F Arambula
Journal:  Chem Commun (Camb)       Date:  2020-06-10       Impact factor: 6.222

5.  Synthesis and Biological Evaluation of Bile Acid Analogues Inhibitory to Clostridium difficile Spore Germination.

Authors:  Kristen L Stoltz; Raymond Erickson; Christopher Staley; Alexa R Weingarden; Erin Romens; Clifford J Steer; Alexander Khoruts; Michael J Sadowsky; Peter I Dosa
Journal:  J Med Chem       Date:  2017-04-12       Impact factor: 7.446

6.  Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment.

Authors:  Steve Seung-Young Lee; Junjie Li; Jien Nee Tai; Timothy L Ratliff; Kinam Park; Ji-Xin Cheng
Journal:  ACS Nano       Date:  2015-02-16       Impact factor: 15.881

7.  Dipeptide Prodrugs of the Glutamate Modulator Riluzole.

Authors:  Jeffrey C Pelletier; Suzie Chen; Haiyan Bian; Raj Shah; Garry R Smith; Jay E Wrobel; Allen B Reitz
Journal:  ACS Med Chem Lett       Date:  2018-06-15       Impact factor: 4.345

8.  Degradation of poly(β-amino ester) gels in alcohols through transesterification: A method to conjugate drugs to polymer matrices.

Authors:  Prachi Gupta; Caroline Lacerda; Vinod Patil; Dipti Biswal; Paritosh Wattamwar; J Zach Hilt; Thomas D Dziubla
Journal:  J Polym Sci A Polym Chem       Date:  2017-03-25       Impact factor: 2.702

9.  Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study.

Authors:  Ni Ai; Richard D Wood; William J Welsh
Journal:  Pharm Res       Date:  2015-03-12       Impact factor: 4.200

10.  Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs.

Authors:  Harinath Chakrapani; Anna E Maciag; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  Org Lett       Date:  2008-10-29       Impact factor: 6.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.